Karyopharm Therapeutics Inc (USD)
KPTI
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range17.34 | 18.41
52-Wk Range |
Last Close17.82
Mkt Cap (m)1,168.07
Dividend yield-
ISINUS48576U1060
Volume838,725
Exchange VenueNAS

Company Profile

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class drugs directed against nuclear transport and related targets to treat cancer and other diseases.

Key Information
Price/Earning-
Price/Book23.47
Price/Sales27.00
P/CF-
Rev Growth (3 year avg)542.75
EPS Growth (3 year avg)-
Operating Margin % -462.85
Net Margin %-488.08
Return on Equity-171.36
Debt/Equity2.51

Documents

Prospectus
en 04/03/2020
Annual Report
en 31/12/2019

Financials

Income Statement
USD201420152016201720182019
Revenue (m)23041
Operating Income (m)-76-119-111-131-180-189
Net Income (m)-76-118-110-129-178-200
Basic EPS-2.43-3.32-2.92-2.81-3.14-3.22
Avg. Diluted Shares Outstanding (m)313638465762
Balance Sheet
USD201420152016201720182019
Current Assets (m)208178132148335279
Non Current Assets (m)13384932716
Total Assets (m)220215180180341295
Current Liabilities (m)121516494746
Total Liabilities (m)------
Total Equity (m)20719816212918350
Cash Flows
USD201420152016201720182019
Operating Cash Flows (m)-51-94-84-74-159-191
Capital Expenditure (m)-3-1-2
Figures are quoted in USD unless stated otherwise
-
No change
$
17.82
Last Price